npas4b Antibody

What is NPAS4B and how does it relate to NPAS4?

NPAS4 (Neuronal PAS domain protein 4) is a basic helix-loop-helix transcription factor belonging to the PAS domain family, which includes important regulatory proteins like Arnt, Clock, BmalI, and Hif1a. NPAS4 functions as an immediate early gene (IEG) that responds rapidly to cellular stimulation and stress. The protein is approximately 87.1 kilodaltons in mass and may also be known as Le-PAS, PASD10, or neuronal PAS domain-containing protein 4 . NPAS4B specifically refers to a particular isoform or ortholog that has been studied in the context of specific research models. When selecting antibodies, researchers should verify the specific epitope recognition to ensure appropriate reactivity with their target protein variant.

In which tissues and cell types is NPAS4 expressed?

NPAS4 was initially characterized in neuronal tissue, but research has demonstrated its expression in non-neuronal tissues as well. Notably, NPAS4 is expressed in pancreatic islets, including both α- and β-cells, but not in exocrine pancreatic tissue . Expression studies using immunofluorescence have revealed significant heterogeneity in NPAS4 staining intensity between islets and in nuclear localization patterns, suggesting dynamic regulation of this protein . When designing experiments, researchers should consider this tissue-specific expression pattern and the potential for variable expression levels when interpreting immunostaining results.

What applications are NPAS4 antibodies validated for?

Commercial NPAS4 antibodies have been validated for multiple applications including:

• Western Blot (WB)

• Enzyme-Linked Immunosorbent Assay (ELISA)

• Immunocytochemistry (ICC)

• Immunofluorescence (IF)

• Immunohistochemistry (IHC)

• Immunohistochemistry on frozen sections (IHC-fr)

• Immunohistochemistry on paraffin sections (IHC-p)

Selection of the appropriate antibody should be based on the specific application requirements and the validated reactivity profiles reported by suppliers.

What species reactivity should I consider when selecting NPAS4 antibodies?

Available NPAS4 antibodies show varied cross-reactivity profiles. Common reactivity patterns include:

• Human (Hu)

• Mouse (Ms)

• Rat (Rt)

• Rabbit (Rb)

• Bovine (Bv)

• Canine (Ca/Dg)

• Guinea Pig (GP)

• Horse (Hr)

• Pig (Pg)

• Sheep (Sh)

For specialized research models, verify the specific ortholog recognition patterns reported by antibody manufacturers to ensure compatibility with your experimental system.

How can I optimize ChIP protocols when using NPAS4 antibodies?

When performing Chromatin Immunoprecipitation (ChIP) with NPAS4 antibodies, consider the following optimization strategies:

• Timing of fixation: Since NPAS4 is an activity-dependent transcription factor, the timing of sample collection is critical. Research has shown significant enrichment of NPAS4 at target gene promoters (such as insulin 1 and insulin 2 promoters) after 2 hours of cellular depolarization .

• Crosslinking conditions: Start with standard 1% formaldehyde for 10 minutes at room temperature, but consider testing different fixation times (8-15 minutes) to optimize crosslinking for NPAS4-DNA interactions.

• Sonication parameters: Aim for chromatin fragments between 200-600bp for optimal NPAS4 binding site resolution.

• Antibody validation: Verify antibody specificity for NPAS4B using Western blot prior to ChIP experiments, as non-specific binding can dramatically reduce ChIP efficiency.

• Controls: Include both negative controls (IgG) and positive controls (regions with known NPAS4 binding, such as the insulin promoters or Rgs2 gene regulatory regions) .

Research has demonstrated 11-fold enrichment at the insulin 1 promoter and 15-fold enrichment at the insulin 2 promoter after depolarization, providing benchmark targets for ChIP optimization .

What are the critical considerations for using NPAS4 antibodies in co-immunoprecipitation studies?

For successful co-immunoprecipitation (Co-IP) experiments with NPAS4 antibodies:

• Lysis conditions: Use gentle, non-denaturing lysis buffers to preserve protein-protein interactions. Consider HEPES-based buffers (pH 7.4-7.6) with 150mM NaCl, 1% NP-40 or 0.5% Triton X-100, and appropriate protease inhibitors.

• Timing considerations: Since NPAS4 expression is activity-dependent, carefully time your experiments to capture the window of maximal NPAS4 expression. Peak expression typically occurs 1-2 hours after stimulation in β-cells .

• Antibody selection: Choose antibodies raised against epitopes that do not interfere with protein-protein interaction domains, particularly avoiding the basic helix-loop-helix and PAS domains if studying interactions with other transcription factors.

• Pre-clearing strategy: Pre-clear lysates with appropriate control IgG to reduce non-specific binding.

• Verification approach: Confirm interactions through reciprocal Co-IPs and consider proximity ligation assays as complementary approaches to validate co-localization.

For studying NPAS4 interactions with transcriptional regulators like Pdx-1, NeuroD1, and MafA, these considerations are particularly important as NPAS4 has been shown to modulate their protein levels in β-cells .

How should I address high background signals when using NPAS4 antibodies for immunohistochemistry?

High background is a common challenge when using NPAS4 antibodies for immunohistochemistry. To address this issue:

• Optimize blocking: Extend blocking time to 2 hours at room temperature using 5-10% normal serum from the species in which the secondary antibody was raised. Adding 0.1-0.3% Triton X-100 can improve blocking efficacy.

• Titrate antibody concentration: Perform a dilution series to determine the optimal concentration. Start with manufacturer recommendations but test 2-3 dilutions above and below this range.

• Increase washing stringency: Add an additional wash step with higher salt concentration (up to 500mM NaCl) to reduce non-specific binding.

• Consider antigen retrieval methods: For pancreatic tissue, citrate buffer (pH 6.0) heat-induced epitope retrieval often works well for NPAS4 detection. Compare multiple retrieval methods if necessary.

• Validate with appropriate controls: Include tissue known to be negative for NPAS4 (e.g., exocrine pancreas) as a negative control . Use knockdown or knockout tissues when available to confirm specificity.

For pancreatic islet staining, be aware that NPAS4 expression shows heterogeneity between islets, which should not be confused with background issues .

What are the key considerations for designing experiments to study activity-dependent regulation of NPAS4?

When designing experiments to study activity-dependent regulation of NPAS4:

• Stimulation protocols: For β-cells and islets, consider:

  • Potassium chloride (30mM KCl) for membrane depolarization

  • Glucose stimulation (16-20mM)

  • GLP-1 receptor agonists like exendin-4 (5-10nM)

  • Combinations of glucose and incretin hormones

• Time course design: Include multiple time points spanning from 15 minutes to 6 hours post-stimulation to capture the transient nature of NPAS4 induction. Research shows peak NPAS4 mRNA expression at approximately 1 hour and protein at 2 hours post-stimulation in β-cells .

• Protein synthesis inhibition: Include cycloheximide treatment arms to confirm the immediate early gene nature of NPAS4 induction (by definition, IEGs are induced without requiring new protein synthesis) .

• Quantification methods:

  • For mRNA: RT-qPCR with appropriate reference genes (β-glucuronidase has been validated for NPAS4 studies)

  • For protein: Western blot with quantitative analysis

  • For localization: Immunofluorescence with nuclear/cytoplasmic ratio analysis

• Downstream target validation: Consider measuring expression of NPAS4 target genes like Rgs2, which shows delayed induction kinetics compared to NPAS4 .

How should contradictory findings regarding NPAS4 effects on insulin gene expression be reconciled?

When encountering contradictory results regarding NPAS4 effects on insulin gene expression:

• Consider experimental context:

  • Acute vs. chronic NPAS4 expression: Transient induction vs. sustained overexpression can have opposing effects

  • Cell types used: MIN6 cells vs. primary islets may respond differently

  • Species differences: Human vs. mouse β-cells may show distinct regulatory patterns

• Analyze direct vs. indirect effects:

  • Direct transcriptional regulation: ChIP data demonstrates NPAS4 enrichment at insulin promoters, suggesting direct repression

  • Indirect regulation: NPAS4 modulates protein levels of other transcription factors (Pdx-1, NeuroD1, MafA) that regulate insulin

• Examine experimental approach:

  • Loss-of-function (siRNA knockdown) shows increased insulin expression

  • Gain-of-function (adenoviral overexpression) shows decreased insulin expression

  • Different assay sensitivities: Reporter assays vs. mRNA quantification vs. protein measurement

• Reconciliation framework:

  • NPAS4 likely serves as a negative feedback regulator that fine-tunes insulin expression during prolonged stimulation

  • The 31-38% reduction in insulin mRNA with NPAS4 overexpression suggests a modulatory rather than all-or-none effect

  • The apparent contradictions may reflect the homeostatic function of NPAS4 in different physiological contexts

What molecular mechanisms explain NPAS4-mediated inhibition of incretin-stimulated insulin secretion?

The molecular mechanisms underlying NPAS4-mediated inhibition of incretin-stimulated insulin secretion involve several coordinated pathways:

• GLP-1 receptor signaling impairment:

  • NPAS4 overexpression shifts the EC50 of exendin-4 from 0.76 to 2.65 nM, indicating reduced receptor sensitivity

  • Reduced cAMP production in response to both exendin-4 and forskolin stimulation with NPAS4 overexpression

• Upregulation of negative regulators:

  • NPAS4 directly binds to regulatory regions of the Rgs2 gene and increases its expression

  • Rgs2 (Regulator of G-protein Signaling 2) is a GTPase-activating protein that negatively regulates G-protein coupled receptor signaling

  • The induction pattern of Rgs2 follows NPAS4 with delayed kinetics, consistent with a transcriptional target relationship

• Insulin content reduction:

  • 57% reduction in insulin content with NPAS4 overexpression contributes to reduced secretory capacity

  • This effect is mediated through both direct inhibition of insulin promoter activity and altered protein levels of key transcription factors

• Selective inhibition pattern:

  • Glucose-stimulated insulin secretion remains largely intact

  • Incretin potentiation is specifically impaired

  • Partial response to direct adenylyl cyclase activation (forskolin/IBMX) suggests multiple levels of regulation

This multi-level regulation represents a sophisticated homeostatic mechanism that preserves core glucose responsiveness while dampening the potentiating effects of incretins during prolonged β-cell stimulation.

How do post-translational modifications affect NPAS4 antibody recognition and experimental outcomes?

Post-translational modifications (PTMs) of NPAS4 can significantly impact antibody recognition and experimental outcomes:

• Common PTMs affecting NPAS4 detection:

  • Phosphorylation: Activity-dependent phosphorylation of NPAS4 may mask or expose epitopes

  • SUMOylation: Can alter protein conformation and epitope accessibility

  • Ubiquitination: May signal protein degradation and affect quantification

• Experimental considerations:

  • Antibody selection: Choose antibodies raised against regions less likely to undergo PTMs

  • Sample preparation: Phosphatase inhibitors are crucial when studying activity-dependent regulation

  • Buffer composition: Denaturing vs. native conditions can dramatically affect PTM-dependent epitope recognition

• Validation approaches:

  • Use multiple antibodies targeting different epitopes to confirm findings

  • Consider phosphorylation-specific antibodies when studying activity-dependent regulation

  • Validate with recombinant proteins containing defined modifications

• Alternative detection methods:

  • Mass spectrometry to characterize PTMs present in your experimental system

  • Proximity ligation assays to study interactions in their native context

  • Genetic tagging (FLAG, HA) when possible to avoid PTM-related detection issues

Understanding the potential impact of PTMs on antibody recognition is particularly important for NPAS4, given its rapid induction and regulation in response to cellular activity and stress conditions.

How can NPAS4 antibodies be utilized to investigate β-cell dysfunction in diabetes research?

NPAS4 antibodies offer valuable tools for investigating β-cell dysfunction in diabetes models:

• Stress response characterization:

  • NPAS4 is induced by ER stressors and can protect against thapsigargin- and palmitate-induced dysfunction and cell death

  • Immunostaining for NPAS4 in diabetic islets can reveal altered stress response patterns

  • Co-staining with ER stress markers (BiP, CHOP) can assess correlation between NPAS4 expression and ER stress severity

• Cytoprotective pathway identification:

  • ChIP-seq using NPAS4 antibodies can identify stress-responsive genes directly regulated by NPAS4

  • Co-IP experiments can reveal stress-specific protein interaction partners

  • Phosphorylation-specific antibodies may help characterize activation patterns under diabetogenic conditions

• Therapeutic target validation:

  • NPAS4 has been proposed as a novel therapeutic target that could both reduce ER stress and cell death while maintaining basal cell function

  • Antibody-based detection of NPAS4 in drug screening assays can help identify compounds that modulate its expression or activity

  • Monitoring NPAS4 levels during interventions can serve as a biomarker for β-cell stress resolution

• Methodological approach:

  • Immunohistochemistry on pancreatic sections from diabetic patients and controls

  • Western blot analysis of islet lysates from various diabetes models

  • Chromatin immunoprecipitation to identify differential binding patterns under diabetic conditions

  • Live-cell imaging with fluorescently tagged antibody fragments to monitor NPAS4 dynamics

This research direction is particularly promising as NPAS4 represents a key activity-dependent regulator that improves β-cell efficiency in the face of stress, potentially offering new therapeutic strategies for type 2 diabetes .